This downregulation not only inhibits the oncogenic signaling mediated by BCR-ABL, but also triggers apoptosis in CML cells, including those harboring the notoriously resistant T315I mutation [92]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.